AdvaMed: N.J. will be hit hard by device tax; Epistem looks to cash in on TB diagnostic;

@FierceMedDev: The FDA is finally moving forward with its device ID plan, but will it actually help keep patients safe? Item | Follow @FierceMedDev

 @MarkHFierce: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @MarkHFierce

 @DamianFierce: MDxHealth has signed a deal with Merck KGaA to provide companion diagnostics for a pipeline cancer drug. Story | Follow @DamianFierce

> In an editorial, AdvaMed CEO Stephen Ubl says, unless it's repealed, the 2.3% device tax will particularly harm New Jersey, hampering small devicemakers' ability to survive and stamping out startups before they have a chance to turn profits. More

> With CE mark in hand, diagnostics firm Epistem is likely to lock down more partnerships for Genedrive, its rapid tuburculosis test. Item

> Scientists are working on a closed-loop implantable device to treat seizures, detecting brain patterns and delivering drugs as needed without external controls. News

> U.K. devicemaker Owen Mumford is investing about $11 million to build a new injector plant in Oxfordshire. Article

> Canadian researchers have discovered that a device designed to improve blood flow in the legs could help prevent thousands of diabetes-related amputations per year. Story

> Startup Harmonic Cold Plasma has secured $1 million to develop its hand-held wound-healing device. Report

Pharma News

@FiercePharma: Spanish drugmakers can't grow at home, so they're looking for international expansion--Bloomberg. More | Follow @FiercePharma

> Sanofi mulls up to 2,000 job cuts in France, unions say. News

> Sanofi chief among then-GSK execs named in DoJ off-label case. Article

> India's anti-brand stance threatens Big Pharma growth. More

> Italy sharpens up for another €1B in health cuts. Story

Biotech News

 @FierceBiotech: Nanofactories can synthesize drugs within the body. More | Follow @FierceBiotech

@JohnCFierce: Roche move spotlights NJ's shrinking role in biopharma R&D. Article | Follow @JohnCFierce

 @RyanMFierce: Software could provide a new measuring tool for Parkinson's during clinical trials. Story | Follow @RyanMFierce

> Sanofi sharpens R&D budget ax as it prepares to cut up to 2,000 jobs. News

> Dr. Reddy's maps out ambitious global plans for biosimilars. Article

> CEO at troubled Cardiome exits in midst of reorganization. Story

Vaccines News

> In $69M IPO bid, GlobeImmune spotlights therapeutic vaccines. Story

> Group tackles dengue vaccine pricing. More

> Soligenix, Infectious Disease Research Institute partner to combat anthrax. Article

> FDA gives Argos green light for kidney cancer immunotherapy. News

Pharma Manufacturing News

 @EricPFierce: China tainted drug capsule scandal leads to new responsibilities for drugmakers. Report | Follow @EricPFierce

> FDA gets device, but not drug tracking .More

> Budget chainsaw may miss Sanofi manufacturing. News

> Glaxo manufacturing must meet special dictates. Story

CRO News

 @NesaNFierce: Argentina is becoming more than the birthplace of Tango, growing in terms of outsourcing. More | Follow @NesaNFierce

> Pernix Therapeutics offers $4.9M for CMO Great Southern Laboratories. Story

> ScinoPharm to build $37M Taiwan plant for cancer injectables. Article

> CMO execs reflect on changing manufacturing front. More

Drug Delivery News

> UPenn turns plant protein into drug-delivery tech. Item

> pSivida eyes FDA approval with trial for Durasert-delivered drug. Story

> InVivo looks to get gel-delivered pain drug on U.S. market. Article

> Northwestern docs deliver siRNA with lotion to stymie cancer. More

> Researchers develop gel to deliver male contraceptive. Story

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.